A citation-based method for searching scientific literature

Megan DeNicola, Jianfeng Du, Zhengke Wang, Naohiro Yano, Ling Zhang, Yigang Wang, Gangjian Qin, Shougang Zhuang, Ting C Zhao. Am J Physiol Endocrinol Metab 2014
Times Cited: 39







List of co-cited articles
344 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice.
Mohammad Hossein Noyan-Ashraf, M Abdul Momen, Kiwon Ban, Al-Muktafi Sadi, Yu-Qing Zhou, Ali M Riazi, Laurie L Baggio, R Mark Henkelman, Mansoor Husain, Daniel J Drucker. Diabetes 2009
405
35

Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways.
Kiwon Ban, M Hossein Noyan-Ashraf, Judith Hoefer, Steffen-Sebastian Bolz, Daniel J Drucker, Mansoor Husain. Circulation 2008
752
33

Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury.
Leo Timmers, José P S Henriques, Dominique P V de Kleijn, J Hans Devries, Hans Kemperman, Paul Steendijk, Cees W J Verlaan, Marjolein Kerver, Jan J Piek, Pieter A Doevendans,[...]. J Am Coll Cardiol 2009
350
33

Exendin-4 protects against post-myocardial infarction remodelling via specific actions on inflammation and the extracellular matrix.
Emma Robinson, Roslyn S Cassidy, Mitchel Tate, Youyou Zhao, Samuel Lockhart, Danielle Calderwood, Rachel Church, Mary K McGahon, Derek P Brazil, Barbara J McDermott,[...]. Basic Res Cardiol 2015
43
30

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.
Benjamin M Scirica, Deepak L Bhatt, Eugene Braunwald, P Gabriel Steg, Jaime Davidson, Boaz Hirshberg, Peter Ohman, Robert Frederich, Stephen D Wiviott, Elaine B Hoffman,[...]. N Engl J Med 2013
28

Glucagon-like peptide-1 and the exenatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure.
Que Liu, Christen Anderson, Anatoly Broyde, Clara Polizzi, Rayne Fernandez, Alain Baron, David G Parkes. Cardiovasc Diabetol 2010
92
25

Inactivation of the cardiomyocyte glucagon-like peptide-1 receptor (GLP-1R) unmasks cardiomyocyte-independent GLP-1R-mediated cardioprotection.
John R Ussher, Laurie L Baggio, Jonathan E Campbell, Erin E Mulvihill, Minsuk Kim, M Golam Kabir, Xiemin Cao, Benjamin M Baranek, Doris A Stoffers, Randy J Seeley,[...]. Mol Metab 2014
80
25

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
Steven P Marso, Gilbert H Daniels, Kirstine Brown-Frandsen, Peter Kristensen, Johannes F E Mann, Michael A Nauck, Steven E Nissen, Stuart Pocock, Neil R Poulter, Lasse S Ravn,[...]. N Engl J Med 2016
25

Alogliptin after acute coronary syndrome in patients with type 2 diabetes.
William B White, Christopher P Cannon, Simon R Heller, Steven E Nissen, Richard M Bergenstal, George L Bakris, Alfonso T Perez, Penny R Fleck, Cyrus R Mehta, Stuart Kupfer,[...]. N Engl J Med 2013
23

Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion.
Lazaros A Nikolaidis, Sunil Mankad, George G Sokos, Glen Miske, Ankur Shah, Dariush Elahi, Richard P Shannon. Circulation 2004
654
23

Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury.
Amal K Bose, Mihaela M Mocanu, Richard D Carr, Christian L Brand, Derek M Yellon. Diabetes 2005
459
23

Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure.
George G Sokos, Lazaros A Nikolaidis, Sunil Mankad, Dariush Elahi, Richard P Shannon. J Card Fail 2006
486
23

Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4.
Masayuki Arakawa, Tomoya Mita, Kosuke Azuma, Chie Ebato, Hiromasa Goto, Takashi Nomiyama, Yoshio Fujitani, Takahisa Hirose, Ryuzo Kawamori, Hirotaka Watada. Diabetes 2010
361
23

Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome.
Marc A Pfeffer, Brian Claggett, Rafael Diaz, Kenneth Dickstein, Hertzel C Gerstein, Lars V Køber, Francesca C Lawson, Lin Ping, Xiaodan Wei, Eldrin F Lewis,[...]. N Engl J Med 2015
23

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Steven P Marso, Stephen C Bain, Agostino Consoli, Freddy G Eliaschewitz, Esteban Jódar, Lawrence A Leiter, Ildiko Lingvay, Julio Rosenstock, Jochen Seufert, Mark L Warren,[...]. N Engl J Med 2016
23

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
20

Chronic glucagon-like peptide-1 infusion sustains left ventricular systolic function and prolongs survival in the spontaneously hypertensive, heart failure-prone rat.
Indu Poornima, Suzanne B Brown, Siva Bhashyam, Pratik Parikh, Hakki Bolukoglu, Richard P Shannon. Circ Heart Fail 2008
144
17

GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure.
Minsuk Kim, Mathew J Platt, Tadao Shibasaki, Susan E Quaggin, Peter H Backx, Susumu Seino, Jeremy A Simpson, Daniel J Drucker. Nat Med 2013
306
17

Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons.
Hiroshi Yamamoto, Charlotte E Lee, Jacob N Marcus, Todd D Williams, J Michael Overton, Marisol E Lopez, Anthony N Hollenberg, Laurie Baggio, Clifford B Saper, Daniel J Drucker,[...]. J Clin Invest 2002
384
17


Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy.
Lazaros A Nikolaidis, Dariush Elahi, Teresa Hentosz, Aaron Doverspike, Rhonda Huerbin, Lee Zourelias, Carol Stolarski, You-tang Shen, Richard P Shannon. Circulation 2004
390
17


Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction.
Jacob Lønborg, Niels Vejlstrup, Henning Kelbæk, Hans Erik Bøtker, Won Yong Kim, Anders B Mathiasen, Erik Jørgensen, Steffen Helqvist, Kari Saunamäki, Peter Clemmensen,[...]. Eur Heart J 2012
387
17

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes.
Jennifer B Green, M Angelyn Bethel, Paul W Armstrong, John B Buse, Samuel S Engel, Jyotsna Garg, Robert Josse, Keith D Kaufman, Joerg Koglin, Scott Korn,[...]. N Engl J Med 2015
17

Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.
Kenneth B Margulies, Adrian F Hernandez, Margaret M Redfield, Michael M Givertz, Guilherme H Oliveira, Robert Cole, Douglas L Mann, David J Whellan, Michael S Kiernan, G Michael Felker,[...]. JAMA 2016
303
17

GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody.
Charles Pyke, R Scott Heller, Rikke K Kirk, Cathrine Ørskov, Steffen Reedtz-Runge, Peter Kaastrup, Anders Hvelplund, Linda Bardram, Dan Calatayud, Lotte Bjerre Knudsen. Endocrinology 2014
417
15

Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice.
Meghan Sauvé, Kiwon Ban, M Abdul Momen, Yu-Qing Zhou, R Mark Henkelman, Mansoor Husain, Daniel J Drucker. Diabetes 2010
220
12

Dipeptidyl peptidase-4 modulates left ventricular dysfunction in chronic heart failure via angiogenesis-dependent and -independent actions.
Toshimasa Shigeta, Morihiko Aoyama, Yasuko K Bando, Akio Monji, Toko Mitsui, Miwa Takatsu, Xiang-Wu Cheng, Takahiro Okumura, Akihiro Hirashiki, Kohzo Nagata,[...]. Circulation 2012
135
12

Selective targeting of glucagon-like peptide-1 signalling as a novel therapeutic approach for cardiovascular disease in diabetes.
Mitchel Tate, Aaron Chong, Emma Robinson, Brian D Green, David J Grieve. Br J Pharmacol 2015
19
26

A glucagon-like peptide-1 analog reverses the molecular pathology and cardiac dysfunction of a mouse model of obesity.
Mohammad Hossein Noyan-Ashraf, Eric Akihiko Shikatani, Irmgard Schuiki, Ilya Mukovozov, Jun Wu, Ren-Ke Li, Allen Volchuk, Lisa Annette Robinson, Filio Billia, Daniel J Drucker,[...]. Circulation 2013
164
12


Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy.
Lazaros A Nikolaidis, Dariush Elahi, You-Tang Shen, Richard P Shannon. Am J Physiol Heart Circ Physiol 2005
209
12

Albiglutide, a long lasting glucagon-like peptide-1 analog, protects the rat heart against ischemia/reperfusion injury: evidence for improving cardiac metabolic efficiency.
Weike Bao, Karpagam Aravindhan, Hasan Alsaid, Thimmaiah Chendrimada, Matthew Szapacs, David R Citerone, Mark R Harpel, Robert N Willette, John J Lepore, Beat M Jucker. PLoS One 2011
69
12

Identification and characterization of GLP-1 receptor-expressing cells using a new transgenic mouse model.
Paul Richards, Helen E Parker, Alice E Adriaenssens, Joshua M Hodgson, Simon C Cork, Stefan Trapp, Fiona M Gribble, Frank Reimann. Diabetes 2014
264
12


Intensive glucose control and macrovascular outcomes in type 2 diabetes.
F M Turnbull, C Abraira, R J Anderson, R P Byington, J P Chalmers, W C Duckworth, G W Evans, H C Gerstein, R R Holman, T E Moritz,[...]. Diabetologia 2009
779
12

Exenatide exerts a PKA-dependent positive inotropic effect in human atrial myocardium: GLP-1R mediated effects in human myocardium.
Markus Wallner, Ewald Kolesnik, Klemens Ablasser, Mounir Khafaga, Paulina Wakula, Senka Ljubojevic, Eva Maria Thon-Gutschi, Harald Sourij, Martin Kapl, Nicholas J Edmunds,[...]. J Mol Cell Cardiol 2015
30
16

Cardioprotective effects of lixisenatide in rat myocardial ischemia-reperfusion injury studies.
Paulus Wohlfart, Wolfgang Linz, Thomas Hübschle, Dominik Linz, Jochen Huber, Sibylle Hess, Daniel Crowther, Ulrich Werner, Hartmut Ruetten. J Transl Med 2013
51
12


10-year follow-up of intensive glucose control in type 2 diabetes.
Rury R Holman, Sanjoy K Paul, M Angelyn Bethel, David R Matthews, H Andrew W Neil. N Engl J Med 2008
12

Dipeptidyl peptidase 4 inhibition increases myocardial glucose uptake in nonischemic cardiomyopathy.
Ronald M Witteles, Khun Visith Keu, Andrew Quon, Homa Tavana, Michael B Fowler. J Card Fail 2012
24
16

Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease.
Thomas Nyström, Mark K Gutniak, Qimin Zhang, Fan Zhang, Jens Juul Holst, Bo Ahrén, Ake Sjöholm. Am J Physiol Endocrinol Metab 2004
499
10

Glucagon-like peptide-1 (GLP-1): effect on kidney hemodynamics and renin-angiotensin-aldosterone system in healthy men.
Jeppe Skov, Anders Dejgaard, Jørgen Frøkiær, Jens Juul Holst, Thomas Jonassen, Søren Rittig, Jens Sandahl Christiansen. J Clin Endocrinol Metab 2013
118
10

Circulating dipeptidyl peptidase IV activity correlates with cardiac dysfunction in human and experimental heart failure.
Leonardo dos Santos, Thiago A Salles, Daniel F Arruda-Junior, Luciene C G Campos, Alexandre C Pereira, Ana Luiza T Barreto, Ednei L Antonio, Alfredo J Mansur, Paulo J F Tucci, José E Krieger,[...]. Circ Heart Fail 2013
87
10

Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men.
Jean-Pierre Gutzwiller, Stefan Tschopp, Andreas Bock, Carlos E Zehnder, Andreas R Huber, Monika Kreyenbuehl, Heike Gutmann, Jürgen Drewe, Christoph Henzen, Burkhard Goeke,[...]. J Clin Endocrinol Metab 2004
280
10

Cardiac function in mice lacking the glucagon-like peptide-1 receptor.
Robert Gros, Xiaomang You, Laurie L Baggio, M Golam Kabir, Al Muktafi Sadi, Imran N Mungrue, Thomas G Parker, Qingling Huang, Daniel J Drucker, Mansoor Husain. Endocrinology 2003
146
10



Biology of incretins: GLP-1 and GIP.
Laurie L Baggio, Daniel J Drucker. Gastroenterology 2007
10

Liraglutide promotes natriuresis but does not increase circulating levels of atrial natriuretic peptide in hypertensive subjects with type 2 diabetes.
Julie A Lovshin, Annette Barnie, Ariana DeAlmeida, Alexander Logan, Bernard Zinman, Daniel J Drucker. Diabetes Care 2015
109
10


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.